Skip to main content
Distance to Care Predicts Clinical Trial Enrollment on COG ALL Clinical Trials: A Report from the Children's Oncology Group.
Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel).
Pharmacokinetics (PK) of Deferasirox in Transfusion Dependent Thalassemia.
Improvement in Iron Burden in Patients with Transfusion-Dependent ß-Thalassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene Therapy: Up to 9 Years of Follow-up.
Genetic Variants in Canonical Wnt Signaling Pathway Associated with Pediatric ITP.
A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update.
A Novel Online Decision Support Tool to Determine Practice Patterns and Concordance with Experts in the Treatment of Patients with Immune Thrombocytopenia.
A Napaac Survey to Understand Practices in Diagnosis and Treatment of Children with Moderate Aplastic Anemia.
Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia.
Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance.